The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Diabetic Peripheral Neuropathy
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
-
The Institute for Liver Health dba Arizona Clinical Trials, Chandler, Arizona, United States, 85225
Headlands Research - Scottsdale, Scottsdale, Arizona, United States, 85260
Orange Grove Family Practice, Tucson, Arizona, United States, 85741
Preferred Research Partners, Little Rock, Arkansas, United States, 72211
Hope Clinical Research, Inc., Canoga Park, California, United States, 91303
Valley Clinical Trials, Inc., Northridge, California, United States, 91325
Northern California Research - Sacramento, Sacramento, California, United States, 95821
CMR of Greater New Haven, LLC, Hamden, Connecticut, United States, 06517
Suncoast Research Group, Miami, Florida, United States, 33135
New Horizon Research Center, Miami, Florida, United States, 33165
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Eli Lilly and Company,
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company
2025-01-31